Congratulations to Researchers from Onyx, Proteolix, Yale, and Cal Tech on the FDA Acceptance of the New Drug Application for Carfilzomib for Multiple Myeloma

kyprolis_web_961532415

 

Onyx announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) submission for carfilzomib, a next generation proteasome inhibitor, for the potential treatment of patients with relapsed and refractory multiple myeloma.  The drug candidate was developed by Proteolix which in licensed the initial discovery from academic researchers at Yale and Cal Tech.

CDD’s Barry Bunin was on one of the early patents to help translate the discovery from academia to industry:  Smyth, M. S.; Laidig, G. J; Borchardt, R. T.; Bunin, B. A.; Crews, C. M.; Musser, J. H.; Schneekloth, J. S.; Chabala, J. C.  Compounds for Enzyme Inhibition.  Patent No. US 2005/0245434 A1; issued 3 Nov 2005 (Proteolix, Inc).

For the full announcement, see the Onyx Pharmaceuticals website:  http://www.onyx-pharm.com/news/onyx-pharmaceuticals-announces-fda-acceptance-of-new-drug-application-for-carfilzomib-for-the-treatment-of-relapsed-and-refractory-multiple-myeloma